melanotan 1 dosage: Frequently asked questions

Recalculate concentration using the actual volume added, not the intended volume, then adjust all subsequent dose volumes accordingly. If you intended 2mL but added 2.5mL to a 10mg vial, your concentration is now 10mg ÷ 2.5mL = 4mg/mL instead of 5mg/mL. To maintain a 1mg dose, draw 0.25mL instead of 0.2mL. The peptide mass hasn't changed. Only its distribution within the solvent. Mark the vial with the corrected concentration to prevent dose calculation errors on subsequent administrations.

Switch to a syringe with finer graduations or reconstitute with more bacteriostatic water to increase dose volume. If your calculation yields 0.03mL but your 0.5mL syringe only has 0.05mL increments, you cannot measure accurately. The mechanical precision isn't there. Reconstitute the same 10mg vial with 5mL instead of 1mL to produce 2mg/mL concentration; now that same 0.5mg dose requires 0.25mL, which falls on a clear tick mark. Diluting the solution doesn't reduce peptide potency. It redistributes the same mass across more volume.

You're overdrawing due to syringe measurement error or failing to account for dead space. If a 10mg vial reconstituted in 2mL should yield ten 0.2mL doses but you're running out after seven, you're drawing closer to 0.28mL per injection. A 40% overdose. Verify your syringe type matches your volume needs and confirm you're reading the meniscus at eye level. Switching to low-dead-space syringes recovers 0.02–0.03mL per injection, effectively adding 1–2 doses per vial on 10-dose protocols.

Discard it. Melanotan-1 undergoes irreversible oxidative degradation at temperatures above 8°C. A single 8-hour ambient temperature excursion reduces peptide potency by an estimated 40–60%, and visual inspection cannot detect this loss. Reconstituted peptide must remain refrigerated at 2–8°C between doses. If refrigeration failure occurs, the solution is no longer reliable for clinical use, and continuing the protocol with degraded peptide produces unpredictable melanin deposition and subtherapeutic photoprotection.

Pigmentation will begin to fade gradually but not disappear immediately. Eumelanin synthesised during the build phase remains in the epidermis for 60–90 days even without further MC1R stimulation—natural keratinocyte turnover cycles melanin-rich cells to the skin surface where they desquamate. Expect L* values to increase (lightening) by 5–8% over 4–6 weeks without maintenance injections. Resume dosing at 1mg every 5 days to halt further fade. You do not need to repeat the load phase unless you've been off protocol for more than 12 weeks.

Increase the dose to 0.06–0.08 mg/kg and verify injection technique. Subcutaneous administration into abdominal fat achieves consistent absorption, while intramuscular injection produces erratic pharmacokinetics. Melanogenesis timelines vary by baseline phototype: individuals with Fitzpatrick type I skin carrying homozygous MC1R loss-of-function variants (R151C, R160W, D294H) may require 21–28 days to show visible change even at higher doses. If no pigmentation occurs after four weeks at 0.08 mg/kg, the peptide may be degraded (storage temperature failure) or the product may not be afamelanotide. Third-party mass spectrometry verification is the only definitive test.

You'll likely experience nausea, facial flushing, and transient hypotension within 60–90 minutes of injection—side effects caused by systemic MC1R and MC4R activation before melanocytes have upregulated tyrosinase capacity. Research from the Melanoma Institute Australia found that 60% of subjects starting at ≥1mg daily without prior titration reported Grade 2 nausea (interfering with daily activity) versus 12% in subjects who followed a load phase protocol. Pigmentation does not occur faster—melanin synthesis is rate-limited by tyrosinase activity, which takes 7–10 days to upregulate regardless of initial dose. Drop to 0.25mg for one week, then escalate gradually.

Patchy pigmentation indicates inconsistent MC1R activation across skin regions. This occurs when injection frequency is irregular or when UV exposure is limited during the loading phase. Melanotan-1 requires baseline melanocyte populations to respond. Areas with low melanocyte density (palms, soles, mucous membranes) do not tan regardless of peptide dose. To correct patchiness, maintain strict injection schedules (same day, same time each week) and ensure moderate UV exposure (10–15 minutes of unprotected midday sun or equivalent UVB from a tanning bed) within 24–48 hours of each injection to trigger melanocyte migration.

Mild diffuse hyperpigmentation (Fitzpatrick scale shift of 1–2 grades) occurs in 12–15% of EPP patients at 0.16mg/kg and resolves spontaneously within 90–120 days of stopping treatment. This is pharmacologically expected. Eumelanin deposition is the therapeutic mechanism. Hyperpigmentation is considered an adverse event only when cosmetically unacceptable to the patient or when accompanied by focal darkening (nevi, freckles), which occurs in <3% of cases and warrants dermatologic evaluation. Dose reduction to 0.12mg/kg for subsequent cycles reduces hyperpigmentation severity but may compromise photoprotection duration by 10–15 days.

Administer the missed dose as soon as you remember if fewer than 24 hours have passed, then resume your regular schedule. If more than 24 hours have passed, skip the missed dose and continue with the next scheduled injection. Do not double-dose. Missing 2–3 doses during the loading phase extends the timeline by approximately the same number of days; melanocyte priming is cumulative but not accelerated by catch-up dosing. The MC1R occupancy required to sustain tyrosinase upregulation decays within 36–48 hours, meaning gaps longer than two days effectively restart the receptor sensitization process.

Increase the next dose to 0.12mg/kg and reassess at day 30 post-injection. Subtherapeutic response at initial titration dose occurs in approximately 35% of EPP patients, particularly those with higher baseline protoporphyrin levels (>2,000 µg/dL erythrocyte protoporphyrin). The 0.08mg/kg starting dose exists to identify hypersensitive responders and minimise first-dose nausea. It is not expected to produce full photoprotection in most patients. Dermatologists managing EPP typically advance to 0.16mg/kg by dose 3 for patients reporting continued phototoxic pain during moderate sun exposure.

Reduce the dose by 30–40% and extend the interval between injections to 96–120 hours. Nausea and flushing are mediated by MC4R activation in the hypothalamus and brainstem. These are dose-dependent side effects that resolve when circulating peptide levels drop. Pre-treating with 25–50 mg of diphenhydramine (Benadryl) 30 minutes before injection blocks histamine release and reduces flushing intensity in 60–70% of users. If symptoms persist at reduced doses, discontinue use. Individual MC4R sensitivity varies and some users cannot tolerate even conservative Melanotan-1 protocols.

Reduce dose by 50% immediately and maintain that lower dose for 5–7 days before attempting escalation again. Severe nausea (defined as inability to eat or vomiting within 2 hours post-injection) indicates MC4R overstimulation, which resolves with receptor downregulation over 5–7 days of consistent lower-dose exposure. Administering ondansetron (Zofran) 30 minutes before injection can mitigate nausea during titration but does not prevent it long-term. If nausea persists at 0.25mg daily, discontinue use. MC4R hypersensitivity is a contraindication.

Nausea occurs in 20–30% of users during the first 3–5 days of loading and typically resolves as the body adapts to elevated alpha-MSH signaling. If nausea persists beyond day 5 or prevents eating, reduce the loading dose to 0.12mg/kg and extend the loading phase to 14 days. This achieves the same cumulative receptor exposure with lower peak plasma levels. Split dosing (half in morning, half in evening) does not reduce nausea and complicates injection schedules without benefit. Antiemetics like ondansetron can be used during the first week if nausea is severe, but most patients tolerate the protocol without pharmaceutical intervention. Our experience: nausea correlates more strongly with injection speed than dose. Slow subcutaneous administration over 30–45 seconds reduces GI irritation compared to rapid bolus injection.

This is the most common protocol failure. One week provides only partial melanocyte priming. You will experience MC1R activation (nausea, flushing) without meaningful eumelanin deposition because melanin synthesis requires 10–14 days to reach protective density. Starting 7 days before UV exposure leaves you vulnerable to sunburn during the critical early exposure period when melanin is still accumulating. If departure is imminent, begin dosing immediately but maintain aggressive sunscreen use (SPF 30–50) for the first 10 days of UV exposure, then gradually reduce reliance as pigmentation develops.

Restart titration from 0.25mg daily rather than resuming at your previous dose. The cAMP signal driving melanogenesis decays within 48–72 hours of stopping injections, and melanocyte tyrosinase expression returns to baseline within 5–7 days. Resuming at 1.0mg after a three-day gap increases side effect severity without accelerating re-pigmentation. The total time to visible tan will extend by approximately 7 days compared to uninterrupted dosing.

Increase maintenance frequency to 0.5mg three times weekly instead of twice weekly. Individual variation in melanocyte turnover rate affects how quickly pigmentation fades once daily dosing stops. Subjects with higher baseline melanocyte apoptosis rates require more frequent maintenance dosing to sustain pigmentation. Clinical data shows maintenance dosing intervals ranging from twice weekly to every other day depending on skin type and baseline melanin density.

Lack of visible pigmentation after 14 days of protocol-compliant dosing indicates one of three issues: insufficient UV exposure (melanin synthesis requires UV-induced p53 signaling), MC1R genetic variants with reduced peptide affinity (common in red-haired phenotypes with MC1R loss-of-function mutations), or denatured peptide from improper storage. Verify reconstituted peptide has been refrigerated continuously at 2–8°C. Increase controlled UV exposure to 80–90% of MED if you have been avoiding UV entirely. If pigmentation remains absent after 21 days with compliant dosing and UV exposure, MC1R genetic testing can confirm receptor functionality.

Maintain the same loading and maintenance doses. Photoprotection and pigmentation are mechanistically inseparable. Increased melanin density is the photoprotective mechanism; you can't achieve one without the other. For patients with photosensitivity disorders using Melanotan-1 medically, the cosmetic darkening is an unavoidable side effect of the therapeutic endpoint (elevated MED). If cosmetic tanning is undesirable, the alternative is strict photoavoidance and high-SPF sunscreen. There is no formulation of Melanotan-1 that provides UV defense without pigmentation. Patients who prefer minimal visible darkening should avoid UV exposure entirely during the loading phase; this produces photoprotection (increased basal melanin) with less stratum corneum pigmentation, though the difference is modest.

If you miss a single dose during the 10-day loading phase, administer it as soon as you remember and continue the sequence. One missed dose delays pigmentation by 24–48 hours but doesn't require restarting. If you miss 2+ consecutive doses, receptor occupancy drops below the saturation threshold and you'll need to extend loading by the number of missed days. Missing doses during loading is more disruptive than during maintenance because you're trying to achieve initial MC1R upregulation, not just sustain it. The melanogenic pathway has a 72-hour memory. Gaps longer than that reset the receptor activation curve.